Pimasertib - Merck Serono/Sanofi

Drug Profile

Pimasertib - Merck Serono/Sanofi

Alternative Names: AS-703026; EMD-1036239; MSC 1936369; MSC 1936369B; MSC1936369A

Latest Information Update: 30 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Santhera Pharmaceuticals
  • Developer Merck Serono; Sanofi
  • Class Amides; Aminopyridines; Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Haematological malignancies; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 30 Aug 2018 Discontinued - Phase-II for Malignant melanoma (First-line therapy, Late-stage disease, Metastatic disease) in Belgium, France, Germany, Israel, Italy, Netherlands, New Zealand, South Africa, Spain, Sweden, Switzerland, United Kingdom, Australia, USA (PO)
  • 24 Jun 2018 Biomarkers information updated
  • 30 Nov 2017 EMD Serono and Sanofi completes a phase II trial in Ovarian cancer (Inoperable/Unresectable, Second-line therapy or greater, Monotherapy, Combination therapy) in USA, Australia, Canada, France, Poland, Italy, Belgium and Spain (PO) (NCT01936363) (EudraCT2013-000902-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top